Voyager Therapeutics, Inc.VYGRNASDAQ
LOADING
|||

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating
Buy
20 analysts·High coverage
85%
Rating Distribution
Strong Buy
00%
Buy
1785%
Hold
315%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 260% higher.

Bear Case
$8.00
+100%
Consensus
$14.40
+260%
Bull Case
$18.00
+350%
Price Range20 analysts
Low
Consensus
High
$8.00
$18.00
Current Target
Current Price
$4.00
Upside to Target
$10.40

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Mar 12, 2025Wells Fargo
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo
Target:$10.00
+162.8%from $3.81
Nov 13, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on Voyager Therapeutics (VYGR)
Target:$18.00
+160.1%from $6.92
Sep 25, 2024Robert W. Baird
Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR)
Target:$18.00
+198.0%from $6.04
May 14, 2024Wedbush
Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush
Target:$8.00
-5.7%from $8.48
Jan 2, 2024Wells Fargo
Wells Fargo Upgrades Voyager Therapeutics (VYGR) to Overweight
Target:$14.00
+55.6%from $9.00
May 10, 2023Truist Financial
Voyager Therapeutics' Seasoned Management And Leading Adeno-Associated Virus Capsid Platform Impress Bullish Analyst
Target:$18.00
+82.2%from $9.88